Scholarlink

Background <p>Type&#xa0;1 diabetes begins as an autoimmune disease and can already be diagnosed in the presymptomatic early stage by detecting at least two positive islet autoantibodies (stage&#xa0;1, International Classification of Diseases, 10th Revision, German Modification [ICD-10-GM]: R76.80; stage&#xa0;2, ICD-10-GM: R73.00). Immunomodulatory therapies can slow disease progression and delay the clinical manifestation of type&#xa0;1 diabetes. In parallel, cell therapy for β‑cell replacement is gaining increasing importance as a&#xa0;strategy to restore endogenous insulin production.</p> Objectives <p>This article provides an overview of the current status of immunotherapies and cell therapies in type&#xa0;1 diabetes.</p> Materials and methods <p>The review “The future of type&#xa0;1 diabetes therapy” by Ziegler et&#xa0;al. (2025) served as the basis. In addition, current guidelines, original articles, and selected studies on immunotherapies and β‑cell replacement therapies were considered.</p> Results <p>With teplizumab, the first disease-modifying therapy for stage&#xa0;2 type&#xa0;1 diabetes is available. It delays the transition to clinically manifest type&#xa0;1 diabetes (stage&#xa0;3) by an average of 2–3 years. Other immunomodulatory therapeutic approaches show preservation of residual β‑cell function in stage&#xa0;3 type&#xa0;1 diabetes but are not yet approved for this indication. Stem-cell-based β‑cell replacement therapies are currently being clinically investigated in people with advanced diabetes and impaired awareness of hypoglycemia.</p> Conclusion <p>Immunotherapies and cell therapies mark a&#xa0;paradigm shift in the treatment of type&#xa0;1 diabetes. In the future, combination therapies will be particularly important to improve the durability of therapeutic effects, as will strategies to protect transplanted cells from alloimmunity and autoimmunity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immuntherapie und Zelltherapie bei Diabetes mellitus Typ 1

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月28日

查看全文
  • Sarah Schill,
  • Lena Schwenker,
  • Franziska Reinmüller,
  • Peter Achenbach,
  • Anette-G. Ziegler

摘要

Background

Type 1 diabetes begins as an autoimmune disease and can already be diagnosed in the presymptomatic early stage by detecting at least two positive islet autoantibodies (stage 1, International Classification of Diseases, 10th Revision, German Modification [ICD-10-GM]: R76.80; stage 2, ICD-10-GM: R73.00). Immunomodulatory therapies can slow disease progression and delay the clinical manifestation of type 1 diabetes. In parallel, cell therapy for β‑cell replacement is gaining increasing importance as a strategy to restore endogenous insulin production.

Objectives

This article provides an overview of the current status of immunotherapies and cell therapies in type 1 diabetes.

Materials and methods

The review “The future of type 1 diabetes therapy” by Ziegler et al. (2025) served as the basis. In addition, current guidelines, original articles, and selected studies on immunotherapies and β‑cell replacement therapies were considered.

Results

With teplizumab, the first disease-modifying therapy for stage 2 type 1 diabetes is available. It delays the transition to clinically manifest type 1 diabetes (stage 3) by an average of 2–3 years. Other immunomodulatory therapeutic approaches show preservation of residual β‑cell function in stage 3 type 1 diabetes but are not yet approved for this indication. Stem-cell-based β‑cell replacement therapies are currently being clinically investigated in people with advanced diabetes and impaired awareness of hypoglycemia.

Conclusion

Immunotherapies and cell therapies mark a paradigm shift in the treatment of type 1 diabetes. In the future, combination therapies will be particularly important to improve the durability of therapeutic effects, as will strategies to protect transplanted cells from alloimmunity and autoimmunity.